Results 41 to 50 of about 3,441 (189)
Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV‑1 [PDF]
, 2019 Drugs that block HIV-1 entry are relatively limited. Enfuvirtide is a 36-residue synthetic peptide that targets gp41 and blocks viral fusion. However, Enfuvirtide-resistant HIV has been reported, and this peptide drug requires daily injection. Previously,
Rachel L. Tennyson (6445370) +9 more
core +1 more source
Interaction Between Enfuvirtide, an Injectable Fusion Inhibitor, and Niacin in an HIV-Infected Patient [PDF]
, 2010 Objective: To report a potential drug-drug interaction between enfuvirtide, an injectable HIV fusion inhibitor, and niacin in an HIV-infected man with dilated cardiomyopathy.
Elizabeth Oates, Kathryn Dzintars
core +1 more source
Microbial Cell Factories, 2011 Background Through modification of the flagellin type III secretion pathway of Bacillus halodurans heterologous peptides could be secreted into the medium as flagellin fusion monomers.
Nxumalo Nolwandle P +3 more
doaj +1 more source
Viruses, 2023 Human immunodeficiency virus type 1 (HIV-1) is characterized by high variability and drug resistance. This has necessitated the development of antivirals with a new chemotype and therapy.
Chao Wang +9 more
doaj +1 more source
Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery
Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju +3 more
wiley +1 more source
gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure [PDF]
, 2007 Enfuvirtide is the first of a new class of antiretroviral drugs that inhibits HIV entry. It is a 36 amino acid synthetic peptide that mimics the HR2 region of the HIV-1 gp41, preventing the fusion of viral and cellular membranes.
Bellagamba, R +26 more
core +1 more source
MicrobiologyOpen, Volume 15, Issue 3, June 2026.Griffithsin, Brevinin‐2, and CCL20 were identified as potent MERS‐CoV fusion inhibitor candidates targeting the HR2 domain through integrated molecular docking, MD simulations, and MM/PBSA analyses. These peptides demonstrated superior binding stability and favorable safety profiles compared to the standard inhibitor, supporting their potential as ...
Nasser Alotaiq +2 more
wiley +1 more source
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations [PDF]
, 2012 Background: For the expression of late viral genes, HIV-1 efficiently exploits the nuclear export by using Rev viral protein, which specifically binds the RNA Rev Responsive Element (RRE). This region is contained within the gp120-gp41 encoding sequence.
Svicher, V +8 more
core +1 more source
Backbone Protecting Groups for Enhanced Peptide and Protein Synthesis
Angewandte Chemie, Volume 137, Issue 33, August 11, 2025.This review provides a comprehensive account of the use of backbone N‐protecting groups in peptide synthesis. It includes detailed synthetic methods relating to their introduction and removal and their application to “difficult” peptides and proteins of biological significance in both academic and industry contexts.
Samuel J. Paravizzini +3 more
wiley +2 more sources
Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level [PDF]
, 2004 Partition of the intrinsically fluorescent HIV fusion inhibitor enfuvirtide into lipidic membranes is relatively high (DeltaG=6.6 kcal (.) mol(-1)) and modulated by cholesterol.
Viega, Salomé +3 more
core +1 more source